Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
hormone receptor +
How you choose between letrozole or exemestane when patients have AIMSS with anastrozole in adjuvant breast cancer therapy?
Related Questions
What are your top takeaways in Breast Cancer from ASCO 2023?
How do you approach the decision for adjuvant chemotherapy in perimenopausal patients with ER+ breast cancer?
Would you treat beyond 10 years of adjuvant hormonal therapy for premenopausal woman with high risk ER+ HER2 negative breast cancer who remain premenopausal at the end of 10 year adjuvant hormonal therapy?
How do you discuss use of tamoxifen in your stage I breast cancer patients who are > 80 years old weighing in risk of VTE with benefit from adjuvant treatment?
What alternate neo-adjuvant backbone chemotherapy would you recommend in a patient with ER+ HER2+ clinical stage II breast CA with severe pan-colitis following a cycle of TCHP with docetaxel?
How would you approach a postmenopausal patient on Letrozole who developed cataracts within the first six months of treatment?
Would you recommend axillary lymph node dissection in a pre-menopausal woman with ER+ PR+ HER2- IDC, s/p lumpectomy and SLN with pT1c pN1 cM0 disease, where 2 sentinel nodes are positive for macrometastasis and 1 SN is positive for micrometastasis?
What is the goal of estradiol levels on ovarian suppression and AI for breast cancer?
How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?
How would you manage a HR+/HER2+ breast cancer patient with no response during neoadjuvant TCHP?
